ZO-1 binds numerous transmembrane and cytoplasmic proteins and is required for assembly of both adherens and tight junctions, but its role in defining barrier properties of an established tight junction is unknown. We depleted ZO-1 in MDCK cells using siRNA methods and observed specific defects in the barrier for large solutes, even though flux through the small claudin pores was unaffected. This permeability increase was accompanied by morphological alterations and reorganization of apical actin and myosin. The permeability defect, and to a lesser extent morphological changes, could be rescued by reexpression of either full-length ZO-1 or an N-terminal construct containing the PDZ, SH3, and GUK domains. ZO-2 knockdown did not replicate either the permeability or morphological phenotypes seen in the ZO-1 knockdown, suggesting that ZO-1 and -2 are not functionally redundant for these functions. Wild-type and knockdown MDCK cells had differing physiological and morphological responses to pharmacologic interventions targeting myosin activity. Use of the ROCK inhibitor Y27632 or myosin inhibitor blebbistatin increased TER in wild-type cells, whereas ZO-1 knockdown monolayers were either unaffected or changed in the opposite direction; paracellular flux and myosin localization were also differentially affected. These studies are the first direct evidence that ZO-1 limits solute permeability in established tight junctions, perhaps by forming a stabilizing link between the barrier and perijunctional actomyosin.
INTRODUCTIONTight junctions form size-and charge-selective barriers to the paracellular movement of solutes and ions across epithelia (Powell, 1981;Madara, 1998). More than 40 different cytoplasmic and transmembrane proteins are located at the junction (Gonzalez-Mariscal et al., 2003;Schneeberger and Lynch, 2004;Guillemot et al., 2008) yet there is limited knowledge of how most contribute to the junction's selective sealing properties. The cytoplasmic protein ZO-1 was the first tight junction protein to be identified (Stevenson et al., 1986). It is a member of the MAGUK family of membraneassociated scaffolding proteins (Funke et al., 2005) and contains protein-binding domains for all the major transmembrane barrier proteins: claudins (Furuse et al., 1998;Itoh et al., 1999), occludin (Furuse et al., 1994;Fanning et al., 1998), tricellulin (Ikenouchi et al., 2005;Riazuddin et al., 2006), JAM-A (Martin-Padura et al., 1998;Ebnet et al., 2000), and several components of the perijunctional network of actin and myosin (Tsukita et al., 2001;Hartsock and Nelson, 2008;Yamazaki et al., 2008). Although ZO-1 gene deletions are embryonic lethal in mice (Katsuno et al., 2008), the depletion of ZO-1 in cultured epithelial cell models (Umeda et al., 2004;McNeil et al., 2006) results in only a delay in barrier formation. Once tight junctions are formed in the ZO-1-depleted cells, TER and flux for large (40 kDa) solutes are reported to be essentially normal (Umeda et al., 2004). There is no direct evidence to date suggesting that ...